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Abstract
Background: As most genital chlamydia infections are asymptomatic, screening is the main way to detect and
cases for treatment. We undertook a systematic review of studies assessing the efficacy of interventions for
increasing the uptake of chlamydia screening in primary care.
Methods: We reviewed studies which compared chlamydia screening in the presence and the absence of an
intervention. The primary endpoints were screening rate or total tests.
Results: We identified 16 intervention strategies; 11 were randomised controlled trials and five observational
studies, 10 targeted females only, five both males and females, and one males only. Of the 15 interventions among
females, six were associated with significant increases in screening rates at the 0.05 level including a multifaceted
quality improvement program that involved provision of a urine jar to patients at registration (44% in intervention
clinics vs. 16% in the control clinic); linking screening to routine Pap smears (6.9% vs. 4.5%), computer alerts for
doctors (12.2% vs. 10.6%); education workshops for clinic staff; internet-based continuing medical education (15.5%
vs. 12.4%); and free sexual health consultations (16.8% vs. 13.2%). Of the six interventions targeting males, two
found significant increases including the multifaceted quality improvement program in which urine jars were
provided to patients at registration (45% vs. 15%); and the offering by doctors of a test to all presenting young
male clients, prior to consultation (29 vs. 4%).
Conclusions: Interventions that promoted the universal offer of a chlamydia test in young people had the greatest
impact on increasing screening in primary care.
Background
Infection with Chlamydia trachomatis is a significant
public health problem. In women it causes adverse
health consequences such as pelvic inflammatory disease
which in turn can lead to tubal factor infertility and
ectopic pregnancy [1,2]. As over 80% of infections are
asymptomatic, screening on the basis of epidemiological
risk factors such as age and sexual history is the main
way to detect cases [1,2]. Clinical guidelines recommend
chlamydia screening in all sexually active young females
in many countries [3-5], and to young males in some
countries [4].
Primary care clinics play an important role in the pre-
vention and management of sexually transmissible infec-
tions (STIs). A large proportion of young people attend
primary care clinics each year for one reason or another
[6,7], and most chlamydial infections are diagnosed in
this setting [6,8]. However, despite the central role of pri-
mary care in chlamydia management, the proportion of
sexually active young people attending these clinics who
are offered screening at the time of their visit is low in
many countries ranging from 3.3% of 15-24 year females
and 1.0% of males in the South East of England in 2006/
07 [9]: and 12.5% of young sexually active females and
3.7% of males in Australia in 2008 [7].
A systematic review in 2006 by Ginige et al identified
four published trials of interventions to increase
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educational packages targeting primary care physicians,
and the elimination of barriers to screening within clinic
systems were effective at increasing screening [10]. Since
then, a number of new publications have reported on
the evaluation of interventions to increase chlamydia
screening in primary care clinics among patients attend-
ing for routine consultations. This systematic review
aimed to provide an updated synthesis of studies exam-
ining the efficacy of these interventions, including the
trials considered in the 2006 review.
Methods
The systematic review was conducted according to the
PRISMA statement [11].
Review strategy
A publication was considered for inclusion if it reported on
the evaluation of an intervention to increase chlamydia
screening rates in a primary care clinic, through a compari-
son with chlamydia screening rates (proportion of patients
screened within a given time period) in a control group or
control time period. A primary care clinic was defined as a
health service that provides the first point of entry into the
health care system, addresses the vast majority of patient
concerns and needs, and is the ongoing focal point for all
of a patient’s health care requirements. This definition
excluded more specialised services, such as sexual health
clinics, family planning clinics, and pharmacies.
Following Ginige et al (2006), who searched the Medline
database for studies prior to 2005 using the words chlamy-
dia, screening, intervention, primary care and GPs, we
used the search terms as listed below, and extended the
search to additional electronic databases (Medline,
PubMed, EMBASE, the Cochrane Controlled Trials Regis-
ter and the Australian New Zealand Clinical Trial Regis-
try), to the end of September 2010. Only English language
publications were included. Reference lists of selected stu-
dies were also checked for other potentially relevant
studies.
1. Chlamydia infections, or Chlamydia, or Chlamydia
trachomatis, AND
2. Testing or screening, AND
3. Intervention, or trial, or intervention studies AND
4. General practice or general practitioner or GP or
primary care
The papers were reviewed and information extracted
by two authors independently. Disagreements were
resolved by discussion and consensus.
Publications were excluded that did not incorporate a
control group; reported on screening rates in the
absence of a specific intervention; described chlamydia
or STI screening programs in clinic or community set-
tings other than primary care; described surveys of
patients or providers about chlamydia screening; or did
not report original data.
For each paper that met the inclusion criteria, infor-
mation was extracted on the clinic location, the target
population, the intervention strategy, the study design,
the sample size, the statistical tests used and the out-
comes of the evaluation including chlamydia screening
rates or number of tests.
Analysis
We conducted a frequency analysis of information
related to the clinic (location, type), intervention type
and evaluation methods (sample size, design, analytical
techniques, time period of the evaluation and reported
outcomes).
T h ep r i m a r yo u t c o m ef o re a c hs t u d yw a st h es c r e e n -
ing rate, defined as the proportion of patients attending
the clinic who were screened for chlamydia. For studies
that did not report this proportion, we accepted the
total number of tests done as an alternative.
From each study, we abstracted the odds ratio (OR) or
relative risk (RR) indicating the proportion tested in the
intervention group compared to controls. For studies
which did not report a measure of this kind we calculated
the outcomes using Stata statistical software [12], includ-
ing 95% confidence intervals, if the necessary data were
provided in the paper.
Results
Search outcomes
Using the search words ‘chlamydia’ and ‘screening’,
‘intervention’ and ‘general practice’, and variations of
these terms, 96 articles were identified and the abstracts
from these articles were reviewed (Figure 1). A total of 81
papers were excluded because they either described inter-
ventions to improve outcomes other than chlamydia
screening (n = 25); described chlamydia or STI screening
programs in clinic or community settings other than pri-
mary care (n = 15); were reviews or commentaries which
did not contain original data (n = 13); described surveys
of patients or providers about chlamydia screening (n =
5); described a cross sectional or cohort study which
reported STI incidence or prevalence, screening rates or
risk factors (n = 4); described mathematical transmission
models or cost-effectiveness analyses of the impact of
chlamydia screening (n = 4); described a study of non-
genital chlamydia (n = 5); described a chlamydia immu-
nological study (n = 1); was a case report (n = 1); there
was no control group (n = 2); the paper did not contain
any data (n = 6).
Overview of papers included
The remaining 15 papers [6,13-26] were included in the
review; four had been the subject of an earlier review by
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Page 2 of 13Ginige and colleagues [13,23-25]. Studies were con-
ducted in Australia (n = 5), the US (n = 5), the UK,
Scotland, Belgium, Denmark and New Zealand (NZ) (1
each). Two papers [19,22] each reported on the evalua-
tion of two distinct intervention strategies, and two
papers reported on the evaluation of the same interven-
tion strategies (one in females, one in males) [23,24] giv-
ing a total of 16 strategies evaluated across the 15
papers. Of the 16 intervention strategies; 10 targeted
females only, five both males and females, and one
males only.
A ss h o w ni nT a b l e1 ,w eg r o u p e dt h e1 6s t r a t e g i e st o
increase chlamydia screening into six broad categories,
based on the methodological descriptions provided in
the reports: medical record prompts [19,22,26]; clinician
incentives [15,21]; alternative specimen collection
approaches [6,17]; clinician education [13,14,25]; patient
education [16]; and quality improvement programs
[20,22-24].
Of the 16 intervention strategies, eleven were described
as having been evaluated using a randomized controlled
trial (RCT) design [13,15,17,19,22-24,26] while five
reported using an observational design with control clinics
or a control period [6,14,16,20,21,25], One of the rando-
mized designs only involved random assignment between
two clinical sites. Because this very limited degree of ran-
domization can not overcome the potential for major con-
founding due to differences between sites that are
unrelated to the intervention, we reclassified it for the pur-
pose of the review as observational [14] Of the other five
observational evaluations, two involved non-random allo-
cation of clinics to the intervention, with comparison
being made to control clinics and to the pre-intervention
period in the intervention clinics [6,21], and the other
three used a before and after design within the same
group of clinics [16,20,25].
The primary study outcomes reported were clinic
screening rates (13 studies) [6,13,15-17,19,21-24,26],
total tests done (two studies) [14,20], and mean number
of tests per clinician (one study) [25]. One of the studies
that reported total tests also described the screening
rate in four of six participating clinics [20]. In one study
the primary outcome data was screening rates at the
clinic level but only one doctor in each clinic partici-
pated in the intervention [13]. In the RCTs, the total
number of participating clinics ranged from 12-191. In
the observational studies, the range was 2-49. Three eva-
luations did not report statistical tests required to deter-
mine if screening rates between intervention and control
groups were significantly different [14,20,21]. None of
the observational studies reported any form of adjust-
ment in their analyses for differences in baseline charac-
teristics, including chlamydia screening rates, between
the intervention and control clinics, although there were
such differences. For example in the NZ study, clients of
intervention clinics were more likely to be of a lower
socioeconomic status, Māori and rural population [21].
Impact of interventions among females
There were 15 intervention strategies which targeted
females. Six of the 15 intervention strategies were signif-
icantly associated with increased chlamydia screening at
the 0.05 level [13,17,19,21,23,26] (Table 1, Figure 2).
A large increase was observed in a multifaceted quality
improvement program targeting the screening of 14-18
year olds, in whom a screening rate of 65% was achieved
i nf e m a l e sb yt h ee n do ft h ep r o g r a mc o m p a r e dt ot h e
21% in the same time period at control clinics (p < 0.001)
[23]. The increase was achieved within a few months, and
sustained for 18 months. Clinicians in the intervention
group participated in a 4-stage clinical improvement
initiative consisting of an baseline analysis of the gap
between current and best screening practice in participat-
ing clinics, capacity building, developing a clinic flow
chart and promotional material, monthly meetings of the
team members to identify barriers to screening and stra-
tegies to overcome them, development of performance
indicators, and introduction of universal urine specimen
collection from all adolescents at registration, prior to
examination (Table 1, Figure 2).
Other strategies that were associated with significant
but smaller increases in screening in females included
linking chlamydia screening with a Pap smear in a RCT
in Australia [17]. In this study, about 25% of all chlamy-
dia screening in both study groups were conducted
among females aged 30-39 years with a very low
Medline 
31 
EMBASE 
55 
PubMed 
53 
Total abstracts 
assessed 
96 
Duplicates 
105 
Cochrane Trial 
Reg 25 
ANZ Trial Reg 
10 
Excluded 
77 
Full articles 
reviewed 
19 
Excluded 
4 
Included studies 
with a control group  
15 
Figure 1 Search results. ANZ = Australia New Zealand
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Page 3 of 13Table 1 Studies of interventions to increase screening in females (n = 15)
Author
surname,
year
Country Intervention
type
Evaluation
design
Clinics
(n)
Target age
group (yrs)
Intervention
phase
Intervention group Control group Statistical
findings
reported**
Crude RR (and 95% CI)
calculated by reviewer**
Patients
(n)
%
screened
Patients
(n)
%
screened
Walker[26]
2010
Aust RCT 66 16-24 During 12098 12.2% 12924 10.6% OR = 1.3
(95%CI:1.1-1.4)
A
Prompt Before 11518 8.3% 11704 8.8%
Scholes[22]
2006
US RCT 23 14-20 During 1777 42.6% 1732 40.8 OR = 1.0
(95%CI:0.9-1.2)
B
McNulty[19]
2008
UK RCT 44 16-24 During -* -* -* -* RR = 1.0
(95%CI:0.8-1.2)
C
Bilardi[15]
2010
Aust RCT 12 16-24 During 1589 13.4% 1792 8.8% OR = 0.9
(95%CI:0.6-1.2)
D
Incentive Before 2662 11.5% 2689 6.2%
During 4018 16.8% 9068 13.2%
Morgan[21]
2009
NZ Non-RCT 49 16-24 Roll out 5368 15.5% 12124 13.7% NR 1.3 (1.2-1.4)
E
Before 2676 13.9% 6077 13.0%
Bowden[17]
2008
Aust Alternative
specimen
collection
RCT 31 16-25 During 16082 6.9% 10794 4.5% OR = 2.1
(95%CI:1.3-3.4)
F
Verhoeven
[25] 2005
Belgium RCT 36 < 35 yr During -* 7# -* 4.72# p = 0.106
G 1.5
E, H
Burstein[18]
2005
US Non-RCT NS 15-26 During -* 32% -* -* NS 1.1
H
Doctor education Before -* 30% -* -*
Armstrong
[14] 2003
Scotland Non-RCT 2 15-24 During -* 146
## -* 138
## NR 1.1
E, H
Before -* 53
## -* 113
##
Allison[13]
2005
US After -* 15.5% -* 12.4%
RCT 191 16-26 During -* 13.3% -* 13.0% p = 0.04
I, J 1.3
H, J
Before -* 16.2% -* 18.9%
McNulty[19]
2008
UK RCT 82 16-24 During -* -* -* -* RR = 1.3
(95%CI:1.1-1.6)
C
Bilardi[16]
2009
Aust Patient education Non-RCT 3 16-24 During 2002 6.4% -* -* p = 0.95
G 1.0 (0.8-1.2)
Before 1548 6.3% -* -*
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3Table 1 Studies of interventions to increase screening in females (n = 15) (Continued)
Schafer[23]
2002
US RCT 10 14-18 During 1092 43.8% 1299 15.6% p < 0.01 2.8 (2.4-3.2)
E
Quality
improvement
program
Before 80 5.0% 86 14.0%
Scholes[22]
2006
US RCT 23 14-25 During 5650 42% 6105 40.1% OR = 1.0
(95%CI:0.9-1.1)
B
Merritt[20]
2007
Australia RCT 6 15-24 Late-
intervention
-* 10.2%^ -* -* NR 1.5
H, I
Before -* 6.7%^ -* -*
**Higher odds ratio or relative risk means intervention leads to greater screening.
Aust-Australia, US = United States, UK = United Kingdom, NZ = New Zealand, RCT = Randomised controlled trial, OR-odds ratio, RR-relative risk, M = male F = female NR = not reported, NS = not significant.
*Information not reported, #mean tests per GP, ##total tests, ^available
for four of six practices
A = Author conducted a mixed effect logistic regression with a 3-level hierarchy (patients, individual GPs and GP clinics)
B = Author conducted chi-square tests and logistic regression model
C = Author conducted a multi-level model with aggregate baseline tests and positivity included as co-variates. Unit of analysis was GP practice
D = Author conducted a mixed effect logistic regression with a 2-level hierarchy (patients, individual GPs)
E = Screening rate in intervention clinic compared to control clinic during intervention period only
F = Author conducted logistic regression adjusted for clustering within general practices = number of female doctors per practices and number of doctors enrolled in the practice were included in the model
G = Author conducted a test for equality in proportions
H = Insufficient information to calculate 95% CI
I = Author conducted an intention to treat analysis at the clinic level comparing mean post-intervention screening rates for the two groups. A general linear model adjusted for pre intervention done and intra
intervention screening rates using repeated-measures analysis
J = Screening rate in intervention clinic compared to control clinic post intervention
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3chlamydia positivity obtained (< 1%). Integration of
computer alerts within patient management systems
based on age group (16-24) and female sex of clients in
Australia, also demonstrated a small increase in
screening [26]. An evaluation of the impact of provision
of funding for free general practice sexual health visits
for registered adolescents under-25 year in New Zealand
reported a 16.8% screening rate among females
Figure 2 Odds ratio or relative risk* of intervention studies to increase chlamydia screening in females, by intervention strategy type (n
= 15). CI = Confidence interval, QIP = quality improvement program *Higher odds ratio or relative risk means intervention leads to greater screenin
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Page 6 of 13attending the intervention clinics, compared to 13.2% in
the control clinics with no other statistical tests reported
[21]. Small but significant increases in chlamydia screen-
ing were also reported due to an interactive educational
workshop for clinic staff promoting screening in 16-24
year old females in the UK [19] and an internet-based
education program for doctors, promoting screening in
16-24 year old females (Table 1, Figure 2) [13].
Two intervention studies reported increases in screen-
ing but did not include any statistical analysis to demon-
strate the increases were significantly different from
control groups [14,20], One was a multi-faceted quality
improvement program in Australia that introduced chla-
mydia screening during practice visits for other pur-
poses. Doctors were trained to developed tactics for
introducing the chlamydia test and had regular meetings
to discuss progress. However, the increase was not uni-
form or sustained [20]. The other study was conducted
in Scotland and introduced an external advisor at one
clinic to raise awareness of chlamydia and train staff on
guidelines, and compared chlamydia screening to
another clinic without an advisor [14]. The number of
chlamydia tests performed in females increased by 176%
during the 6 month period when the advisor was pre-
sent compared to a six month period before, with 70%
of tests conducted by practice nurses. In the control
clinics screening only increased by 22% (Table 1, Figure
2) [14].
The remaining eight intervention strategies that did
not result in an increase in chlamydia screening were: a
written chart prompt in the US [22]; an educational
package (video and text) on communication skills for
sexual history taking in Belgium [25]; clinician referral
of patients to an interactive website called “Youth Check
Your Risk’ post-consultation in Australia [16]; laboratory
forms modified to include information about chlamydia
screening in the UK [19]; screening recommendations
and provider training in the US [18]; a $5 (AUD) incen-
tive in Australia [15]; and a multifaceted quality
improvement program in the US [22]. The quality
improvement program included selecting ‘leaders’ within
each clinic, an initial training session, regular feedback
on screening performance, provision of guidelines, a
prompt with Pap test, posters and chlamydia informa-
tion. The control group received the standard chlamydia
screening guideline - this was placed on each clinic’s
intranet and all physicians were advised of its posting.
The intervention did not significantly affect overall
screening rates, but did lead to a significant increase in
screening in women having a Pap test (74.6% versus
70.4%, p = 0.04) and a significant increase in screening
in women undergoing a physical examination (64.4%
versus 59.7%, p < 0.01) (Table 1, Figure 2).
Impact of interventions among males
Of the six intervention strategies which targeted males,
two were significantly associated with increased chlamy-
dia screening [6,24]. The greatest impact (673%
increase) in chlamydia screening was observed in a Dan-
ish study in which doctors were asked to test all 16-25
year old males whom they saw for any reason, by use of
a first-catch urine sample. Control clinics comprised all
other clinics in Denmark. Baseline screening in control
and intervention clinics was 3.4% and 3.7% respectively
and over a 12 month period following the intervention,
the study found screening rates were 29% in the inter-
vention clinics compared with 4% in the control clinics
(p < 0.001) [6]. The multifaceted quality improvement
which achieved high screening rates in females [24], also
led to a large increase in 14-18 year old males, in whom
uptake of 49% was achieved by the end of the program
compared to the 5% in the same time period at control
clinics (p < 0.001) [24]. The increase was achieved
within a few months, and sustained for at least 18
months (Table 2, Figure 3).
Two intervention studies reported increases in screen-
ing in males but did not include any statistical analysis
to demonstrate whether the increases were significantly
different from control groups [14,20]. One was the
multi-faceted quality improvement program in Australia
that introduced chlamydia screening during practice vis-
its for other purposes [20]. The second study was con-
ducted in Scotland and introduced an external advisor
at one clinic to raise awareness of chlamydia and train
staff on guidelines, and compared another clinic where
there was no advisor [14]. The number of chlamydia
tests performed in males in a six month period before
the intervention was 4, increasing to 16 during the 6
month period when the advisor was present, compared
with the control clinic clinics where 8 tests were con-
ducted before the intervention, and 10 when the advisor
was present (Table 2, Figure 3).
The remaining two intervention strategies that did not
result in an increase in chlamydia screening were:
screening recommendations and provider training in the
US [18]; and provision of funding for free general prac-
tice sexual health visits for registered adolescents under-
25 year in New Zealand [21] (Table 2, Figure 3).
Interventions which targeted males and females
Five studies targeted both males and females
[14,16,20,21,23,24], and four of these found a greater
increase in screening in males, compared with females
(Table 2, Figure 3) [14,16,21,23,24], while one which
used the strategy of linking screening with women’s
health-related consultations demonstrated a greater
increase in screening in females (Table 3) [20].
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Page 7 of 13Table 2 Studies of interventions to increase screening in males (n = 6)
Author
surname,
year
Country Intervention
type
Evaluation
design
Clinics
(n)
Target age
group (yrs)
Intervention
phase
Intervention group Control group Statistical
findings
reported**
Crude RR (and 95% CI)
calculated by reviewer**
Patients
(n)
%
screened
Patients
(n)
%
screened
During 4190 4.2% 8524 2.1%
Morgan[21]
2009
NZ Incentive Non-RCT 49 16-24 Roll out 5588 3.4% 11333 2.1% NR 2.0 (1.6-2.5)
A
Before 2833 3.0% 5529 1.7%
Anderson[6]
2005
Denmark Alternative
specimen
collection
Non-RCT 3 16-25 During 617 29.4% 11204 3.8% p < 0.01
B 7.7 (6.6-9.0)
A
Before 607 3.7% 12007 3.4%
Armstrong
[14] 2003
Scotland Doctor education Non-RCT 2 15-24 During -* 16^ -* 10^ NR 1.6
C, D
Before -* 4^ -* 8^
Bilardi[16]
2009
Aust Patient education Non-RCT 3 16-24 During 965 3.0% -* -* p = 0.77
B 1.1 (0.7-2.0)
Before 732 2.7% -* -*
Tebb[24]
2005
US RCT 10 14-18 During 990 44.9% 1024 15.1% p < 0.01 3.0 (2.5-3.5)
Quality
improvement
program
Before 76 2.6% 61 7.0%
Merritt[20]
2007
Australia RCT 6 15-24 Late-
intervention
-* 6.3%# -* -* NR 1.4
C
Before -* 4.5%# -* -*
** Higher odds ratio or relative risk means intervention leads to greater screening
Aust-Australia, US = United States, UK = United Kingdom, NZ = New Zealand, RCT = Randomised controlled trial, OR-odds ratio, RR-relative risk, M = male F = female NR = not reported,*Information not reported,
^total tests # available for four of six practices
A = Screening rate in intervention clinic compared to control clinic during intervention period only
B = Author conducted a test for equality in proportions
C = Insufficient information to reviewers to calculate 95% CI
D = Reviewers compared total tests in intervention clinic to control clinic during intervention period only
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3Figure 3 Odds ratio or relative risk* of intervention studies to increase chlamydia screening in males, by intervention strategy type (n
=6 ) . CI = Confidence interval, QIP = quality improvement program, *Higher odds ratio or relative risk means intervention leads to greater
screening.
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In this review, we found that a variety of new approaches
are being evaluated for their potential to increase uptake
of chlamydia screening among young people attending
primary care clinics. A range of potentially effective stra-
tegies were identified in these studies, with six out of the
15 interventions targeting young females and two of the
six interventions among young males finding statistically
significant increases in screening rates.
The two studies with greatest effect from the US and
Denmark, involved systems change to enable all patients
to be offered a chlamydia test. In contrast, the effect of
the multi-faceted quality improvement programs by
Scholes [22] and Merritt [20] which found no or limited
Table 3 Studies of interventions to increase screening in both sexes, by sex (n = 5)
Author
surname,
year
Intervention
type
Sex Intervention
phase
Intervention group Control group Statistical
findings
reported**
Crude RR (95% CI)
calculated by reviewer**
Patients
(n)
%
screened
Patients
(n)
%
screened
During 4018 16.8% 9068 13.2%
F Roll out 5368 15.5% 12124 13.7% NR 1.3 (1.2-1.4)
Morgan[21]
2009
Incentive Before 2676 13.9% 6077 13.0%
During 4190 4.2% 8524 2.1%
M Roll out 5588 3.4% 11333 2.1% p = 0.05
A 2.0 (1.6-2.5)
Before 2833 3.0% 5529 1.7%
Merritt[20]
2007
Quality
improvement
program
F Late-
intervention
-* 10.2%
C -* -* NR 1.5
B
Before -* 6.7%
C -* -*
M Late-
intervention
-* 6.3%
C -* -* NR 1.4
B
Before -* 4.5%
C -* -*
F During -* 146^ -* 138^ NR 1.1
B, D
Armstrong
[14] 2010
Doctor education Before -* 53^ -* 113^
M During -* 16^ -* 10^ NR 1.6
B, D
Before -* 4^ -* 8^
Bilardi[16]
2009
Patient education F During 2002 6.4% -* -* 1.0
E 1.0 (0.8-1.2)
Before 1548 6.3% -* -*
M During 995 3.0% -* -* 0.8
E 1.1 (0.7-2.0)
Before 752 2.7% -* -*
Schafer[23]
2002,
Quality
improvement
program
F During 1092 43.8% 1299 15.6% p < 0.01
F 2.8 (2.4-3.2)
Tebb[24]
2005
Before 80 5.0% 86 14.0%
M During 990 44.9% 1024 15.1% p < 0.01
G 3.0 (2.5-3.5)
Before 76 2.6% 61 7.0%
** Higher odds ratio or relative risk means intervention leads to greater screening
OR-odds ratio, RR-relative risk, * Information not reported, M = male F = female, NR = not reported
^Total tests
A = Authors conducted a t-test for differences in the proportion of tests conducted in males and 16-24 year olds in the intervention practices compared to
control practices
B = Insufficient information to reviewers to calculate 95% CI
C = Screening rates based on 4 of the six clinics in the intervention clinics only
D = Reviewers compared total tests in intervention clinic to control clinic during intervention period only
E = Author conducted a test for equality in proportions
F = Authors assessed the statistical significance of the time by group effect using an F test
G = Authors adjusted for differences in ethnicity between study groups at baseline
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Page 10 of 13increases in screening rates, may have been constrained
because the interventions didn’t cause sufficient systems
change to results in the universal offer of screening,
instead it was more opportunistic screening often linked
with Pap smears. However in the study by Scholes [22]
the lack of effect may also have been because the screen-
ing rates in the control population were already relatively
high (40.1%). This study placed standard chlamydia
screening guidelines on each clinic’s intranet in the inter-
vention and control clinics, which in turn alerted all doc-
tors of the need for screening.
The main limitation of linking chlamydia screening
with Pap smears is that it is unlikely to capture young
women (< 20 years) who are ineligible for Pap smears in
most developed countries, as demonstrated the study by
Armstrong [14], where most of the increased screening
occurred outside the target age range, and Bowden where
25% of chlamydia screening in both study groups were
conducted among women aged 30-39 years [17]. Further-
more the extent of chlamydia screening would be reliant
on recommended Pap smear screening intervals and age
groups which do not necessarily coincide with that
recommended for chlamydia screening. The strength of
this strategy is that screening could be conducted by
practice nurses during women’s health consultations,
overcoming the barriers of insufficient time raised by
clinicians [20,27-29], and concerns that discussing chla-
mydia in a consultation unrelated to sexual health might
upset patients [20,27,28,30].
Two doctor education strategies resulted in small but
statistically significant increases in screening; interactive
education workshops in general practice clinics in the UK
[19], and internet-based Continuing Medical Education
(CME), involving 4 modules released every 3 months to
primary care physician offices in the US [13]. The interac-
tive workshop is likely to require significant staff resources
to roll out at a national level. The CME strategy may be
cheaper but would be unlikely to reach all clinicians, with
CME activities generally taken up by those clinicians inter-
ested in the area of sexual health.
Computer alerts were also shown in one study in
Australia to achieve a small improvement in provider
behaviour [26]. These findings are consistent with a
Cochrane review on the effects of on-screen, point of
care computer reminders on processes and outcomes of
care, which found that computer reminders achieved a
median improvement in process adherence of 3.8%
(IQR: 0.4% to 16.3%) for test ordering [31]. In contrast,
more passive prompts such as attaching a reminder
sticker to medical records [19], and including chlamydia
information on laboratory result forms [22], did not sig-
nificantly increased chlamydia screening.
Although Bilardi demonstrated that a small incentive
paid to practitioners did not increase chlamydia screening
rates in Australia [15], the study was limited by the fact
that clinicians did not receive the payment until the con-
clusion of the trial and there was limited contact and
ongoing communication from study investigators during
the trial.(Personal communication - Hocking) The authors
recommended future studies should include a higher
incentive, and/or be associated with more regular feedback
[15]. Incentive payments were used in the chlamydia
screening pilots conducted in the UK. General practi-
tioners were reimbursed up to £20 per eligible person
screened, with screening acceptance rates within clinics of
up to 81% [32]. However, once the chlamydia screening
program was rolled out across the country, incentive pay-
ments were removed and screening participation rates
within clinics fell to below 10% [33], Incentive payments
were offered to general practitioners to enrol patients for
chlamydia screening in Amsterdam with 94% acceptance
[34]. However, without RCT evidence, it is not possible to
predict how well general practitioners would respond to
an incentive payment to increase chlamydia screening
rates.
None of the studies specifically explored the role prac-
tice nurses or other clinic staff could play in chlamydia
screening in primary care, although in the study by Arm-
strong et al [14] practice nurses conducted 70% of screen-
ing by linking it with Pap smears, and in the study by
Shafer [23] and Tebb [24] the urine jar was given to
patients by reception staff at registration, prior to the
examination. It is possible that practice nurses, and other
generalist accredited health workers could play a greater
role in chlamydia screening in primary care clinics.
This review has some methodological limitations. First,
we did not search the grey literature so it is possible that
some evaluations were not identified, particularly those
with a negative outcome. Second, it is possible that in the
observational studies as the intervention was not rando-
mised any imbalances in factors that may have influenced
chlamydia screening rates may have biased the study find-
ings. Third, the populations and health care systems in the
study settings also varied, so the extent to which the find-
ings would apply to other settings is uncertain. For exam-
ple, the multi-faceted quality improvement intervention
reported by Shafer [23] and Tebb [24] was conducted in
paediatric clinics whereas as a number of other studies
were in general practice clinics. Fourth, due to the hetero-
geneity of the interventions and outcomes we were unable
to pool the outcomes to determine a summary effect.
To maximise the value of future evaluations, attention
should be paid to methodological issues, including con-
ducting statistical tests for significance, taking into account
the pre-intervention screening rates or differences in other
baseline characteristics into the analysis, and reporting
screening rates rather that total tests done. The lack of
reporting of screening rate in some studies is likely to be
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Page 11 of 13related to the need to obtain the number of unique
patients from general practice patient management sys-
tems, which can now be facilitated through data extraction
software [35].
The question remains as to which of these strategies
should be employed in primary care to increase chlamydia
screening. It is not clear which would be the most cost-
effective due to the absence of costing data for all the stra-
tegies to enable comparison of impact per unit cost. While
the effect of the intervention seen in the study by Shafer
[23] and Tebb [24] appeared to be relatively large, the
intensity and complexity of the strategies employed may
be too difficult to implement universally. By contrast, the
computer alert evaluated by Walker and colleagues [26]
would be easier to disseminate with little impact on a gen-
eral practitioner’s time but would not achieve coverage
levels of sufficient magnitude to have an impact on popu-
lation prevalence as demonstrated in mathematical model-
ling [36]. Sustainability of the interventions on chlamydia
screening is another issue which was not specifically
addressed by most studies and this factor should also be
considered in selecting appropriate strategies.
Conclusion
Despite the limitations to the studies published, it appears
that interventions that provide easy and systematic means
of offering a chlamydia test to all eligible clients had the
greatest impact on increasing screening in primary care.
Our review focused on studies of young people already
attending primary care settings. A fundamental determi-
nant of the success of any clinic-based strategy is the
extent to which young people can access clinical services
for their sexual health needs. Therefore in applying our
findings to population level health advocacy, it is necessary
to consider the level of access to primary care clinics in
that setting, and the potential to supplement existing clini-
cal services with strategies such as testing programs in
non-clinical settings [37].
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